Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Iptacopan bulk supplier for pharma manufacturers

Iptacopan 200mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 200mg

Reference Brands: Fabhalta (USA/EU)

Category: Immune Disorder

Iptacopan is an oral complement factor B inhibitor developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder in which red blood cells are destroyed by the immune system. By inhibiting factor B, Iptacopan prevents the activation of the alternative complement pathway, reducing hemolysis and improving hemoglobin levels. It is taken orally and offers a convenient alternative to intravenous complement inhibitors like eculizumab or ravulizumab.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Iptacopan — third party manufacturing & bulk supply

Iptacopan 200mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Iptacopan listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Iptacopan →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Iptacopan is used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes the destruction of red blood cells. It is also being studied for use in other complement-mediated diseases.

Iptacopan is made from a small-molecule selective inhibitor of complement factor B, which blocks the alternative complement pathway and prevents red blood cell destruction.

The trade name of Iptacopan is Fabhalta.

Iptacopan is made by Novartis Pharmaceuticals.

The generic name of the product is Iptacopan.

The brand name of Iptacopan is Fabhalta.

Iptacopan is manufactured by Novartis Pharmaceuticals in Switzerland and distributed globally.

Related Products

Etrasimod Arginine

Strength:
2 mg, 4 mg, 6 mg

Form: Tablets

Reference Brands: Velsipity (USA)

View Details
Avacopan

Strength:
10 mg

Form: Capsules

Reference Brands: Tavneos (USA/EU)

View Details
Fostamatinib Disodium

Strength:
100 mg, 150 mg

Form: Tablets

Reference Brands: Tavalisse (USA)

View Details
Deucravacitinib

Strength:
6 mg

Form: Tablet

Reference Brands: Sotyktu (USA/EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.